FDA Delays Approval For MannKind's Inhaled Insulin Afrezza, Stoking Confusion
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency will miss the Jan. 16 action date for the NDA due to a manufacturing inspection; but how the potential length of the delay remains to be seen.
You may also be interested in...
Another Delay For MannKind's Inhaled Insulin As FDA Issues 'Complete Response' Letter
Biotech's share price slides as most analysts question viability going forward of Afrezza program.
Another Delay For MannKind's Inhaled Insulin As FDA Issues 'Complete Response' Letter
Biotech's share price slides as most analysts question viability going forward of Afrezza program.
Biocon Files IND For Oral Insulin In U.S.; Launch In India Likely In 2011
MUMBAI - Amidst a row over the safety and absorption profile of inhaled insulins, Biocon - which steadily advanced its orally-delivered insulin IN-105 into Phase III trials in India - has now filed an investigational new drug application with U.S. FDA